U.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb's CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) in Adults and Pediatric Patients*

The U.S. FDA approved an expanded indication for Bristol Myers Squibb's CAMZYOS to treat symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adult and pediatric patients. The label expansion broadens the addressable patient population for CAMZYOS and is a positive commercial catalyst for BMS's cardiovascular portfolio.